What We Can Learn From Synergy Pharmaceuticals' Disastrous News

What We Can Learn From Synergy Pharmaceuticals' Disastrous News

Source: 
Motley Fool
snippet: 

Synergy Pharmaceuticals (NASDAQ:SGYP) beat the odds by successfully winning FDA approval of Trulance last year, but it may not matter. Recently, management warned it's struggling to renegotiate its debt, and that increases the risk of its bankruptcy.